Truist Financial Keeps Their Buy Rating on Disc Medicine (IRON)
In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on Disc Medicine, with a price target of $83.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Brill covers the Healthcare sector, focusing on stocks such as Neurocrine, Disc Medicine, and Harmony Biosciences Holdings. According to TipRanks, Brill has an average return of 10.8% and a 51.27% success rate on recommended stocks.
In addition to Truist Financial, Disc Medicine also received a Buy from BMO Capital’s Evan Seigerman in a report issued today. However, yesterday, TipRanks – Anthropic reiterated a Hold rating on Disc Medicine (NASDAQ: IRON).
Based on Disc Medicine’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $60.53 million. In comparison, last year the company had a GAAP net loss of $29.46 million
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRON in relation to earlier this year. Earlier this month, Jean M. Franchi, the CFO of IRON sold 4,075.00 shares for a total of $256,154.50.
Read More on IRON:
Disclaimer & DisclosureReport an Issue
- Disc Medicine: Bitopertin’s De-Risked Path to Approval Supports Buy Rating
- Disc Medicine: Strong Cash Runway and Bitopertin Upside Support Buy Rating Despite Regulatory Setbacks
- Disc Medicine reports FY25 EPS ($6.01) vs ($3.96) last year
- Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients
- Disc Medicine price target lowered to $88 from $110 at Wedbush
